Serum Fatty Acid-Binding Protein 4 Is a Predictor of Cardiovascular Events in End-Stage Renal Disease
Open Access
- 10 November 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (11) , e27356
Abstract
Fatty acid-binding protein 4 (FABP4/A-FABP/aP2), a lipid chaperone, is expressed in both adipocytes and macrophages. Recent studies have shown that FABP4 is secreted from adipocytes and that FABP4 level is associated with obesity, insulin resistance, and atherosclerosis. However, little is known about the impact of FABP4 concentrations on prognosis. We tested the hypothesis that FABP4 level predicts prognosis of patients with end-stage renal disease (ESRD), a group at high risk for atherosclerosis-associated morbidity and mortality. Biochemical markers including FABP4 were determined in 61 ESRD patients on chronic hemodialysis (HD). Serum FABP4 level in females (404.2±30.5 ng/ml) was significantly higher than that in males (315.8±30.0 ng/ml), and the levels in ESRD patients were about 20-times higher than those in age-, gender- and body mass index (BMI)-matched control subjects with normal renal function. FABP4 level was decreased by 57.2% after HD and was positively correlated with blood pressure, BMI, and levels of lipids and insulin. Multiple regression analysis indicated that HD duration, BMI, and triglycerides level were independent determinants for FABP4 level. ESRD patients with high FABP4 levels had higher cardiovascular mortality during the 7-year follow-up period. Cox proportional hazard regression analysis showed that logarithmically transformed FABP4 level was an independent predictor of cardiovascular death adjusted for age, gender, HD duration, BMI, and triglycerides level (hazard ratio, 7.75; 95% CI, 1.05–25.31). These findings suggest that FABP4 level, being related to adiposity and metabolic disorders, is a novel predictor of cardiovascular mortality in ESRD.Keywords
This publication has 22 references indexed in Scilit:
- Circulating Levels of Adipocyte and Epidermal Fatty Acid–Binding Proteins in Relation to Nephropathy Staging and Macrovascular Complications in Type 2 Diabetic PatientsDiabetes Care, 2009
- Serum levels of adipocyte fatty acid‐binding protein (AFABP) are increased in chronic haemodialysis (CD)Clinical Endocrinology, 2008
- Adipocyte/macrophage fatty acid–binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in miceJournal of Clinical Investigation, 2008
- Fatty acid-binding proteins: role in metabolic diseases and potential as drug targetsNature Reviews Drug Discovery, 2008
- Serum Adipocyte Fatty Acid–Binding Protein as a New Biomarker Predicting the Development of Type 2 DiabetesDiabetes Care, 2007
- Serum Levels of Adipokine Retinol-Binding Protein-4 in Relation to Renal FunctionDiabetes Care, 2007
- Serum Adipocyte Fatty Acid-Binding Protein Levels Were Independently Associated With Carotid AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2Nature, 2007
- A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular diseaseProceedings of the National Academy of Sciences, 2006
- Adipocyte Fatty Acid–Binding Protein Is a Plasma Biomarker Closely Associated with Obesity and Metabolic SyndromeClinical Chemistry, 2006